Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: Results from a retrospective hospital-based cohort study

Drug Safety

Volumn 34, Issue 12, 2011, Pages 1151-1160

  Ten Berg, Maarten J ^a,b   Van Den Bemt, Patricia M L A ^a,c   Shantakumar, Sumitra ^d   Bennett, Dimitri ^d   Voest, Emile E ^b   Huisman, Albert ^b   Van Solinge, Wouter W ^a,b   Egberts, Toine C G ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Cancer; Cisplatin; Gemcitabine; Haematological disorders; Oxaliplatin; Paclitaxel; Thrombocytopenia

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GEMCITABINE; OXALIPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 81055123624     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11594310-000000000-00000     Document Type: Article

References (22)

1. Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia: current and emerging management strategies. Am J Cancer 2006; 5 (6): 371-82 (Pubitemid 46224855)
2. Zeuner A, Signore M, Martinetti D, et al. Chemotherapyinduced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res 2007; 67 (10): 4767-73 (Pubitemid 46910184)
3. ten Berg MJ, Huisman A, van den Bemt PML A, et al. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007; 45 (1): 13-9 (Pubitemid 46155553)
4. Fritz A, Percy C, Jack A, et al., editors. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva: World Health Organization, 2001
5. Cancer Therapy Evaluation Program, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events, version 3 [online]. Available from URL: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf [Accessed 2010 Nov 18]
6. Dutcher JP, Schiffer CA, Aisner J, et al. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors. Cancer 1984; 53 (3): 557-62 (Pubitemid 14182736)
7. Elting LS, Rubenstein EB, Loewy J, et al. Incidence and outcomes of chemotherapy-induced thrombocytopenia in patients with solid tumors [abstract]. Support Care Cancer 1996; 4: 238
8. Goldberg GL, Gibbon DG, Smith HO, et al. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 1994; 12 (11): 2317-20 (Pubitemid 24346701)
9. Wu Y, Aravind S, Ranganathan G, et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther 2009; 31 (Pt 2): 2416-32
10. Kuderer NM, Francis CW, Crawford J, et al. A prediction model for chemotherapy-associated thrombocytopenia in cancer patients [abstract]. J Clin Oncol 2006; 24 (18 Suppl.): 8616
11. Alberts DS, Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 1998; 3 (1): 15-34 (Pubitemid 28106719)
12. Meyboom RH, Lindquist M, Egberts AC. An ABC of drugrelated problems. Drug Saf 2000; 22 (6): 415-23
13. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329 (7456): 44-7 (Pubitemid 38870007)
14. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20 (3): 292-307 (Pubitemid 30140747)
15. BegM S, Komrokji RS, Ahmed K, et al. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol 2008; 62 (5): 925-7
16. Curtis BR, Kaliszewski J, Marques MB, et al. Immunemediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81 (3): 193-8
17. Pavic M, Moncharmont P, Seve P, et al. Oxaliplatin-induced immune thrombocytopenia. Gastroenterol Clin Biol 2006; 30 (5): 797-8
18. James E, Podoltsev N, Salehi E, et al. Oxaliplatin-induced immune thrombocytopenia: another cumulative dosedependent side effect? Clin Colorectal Cancer 2009; 8 (4): 220-4
19. Happe LE, Farrelly EM, Stanford RH, et al. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries. J Thromb Thrombolysis 2008; 26 (2): 125-31
20. ten Berg MJ, van Solinge WW, van den Bemt PML A, et al. Platelet measurements versus discharge diagnoses for identification of patients with potential drug-induced thrombocytopenia: a cross-sectional study in the netherlands. Drug Saf 2009; 32 (1): 69-76
21. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98 (16): 1108-17 (Pubitemid 44288785)
22. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002; 20 (24): 4636-42 (Pubitemid 36025279)